ArticleScientific reports2025
Attention-enhanced hybrid U-Net for prostate cancer grading and explainability.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Recent advances in discriminating prostate cancer from benign prostatic diseases in the pre-biopsy population.Medical oncology (Northwood, London, England) · 2026Review
- X-Pruning: a dual-stream information fusion mammography diagnosis network based on pruned transformer and cross-attention mechanism.Quantitative imaging in medicine and surgery · 2026Article
- Shifting from black box decisions to informed decision-making in using artificial intelligence to analyze prostate MRI.Abdominal radiology (New York) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Prostate cancer remains a leading cause of mortality, necessitating precise histopathological segmentation for accurate Gleason Grade assessment. However, existing deep learning-based segmentation models lack contextual awareness and explainability, leading to inconsistent performance across heterogeneous tissue structures. Conventional U-Net architectures and CNN-based approaches struggle with capturing long-range dependencies and fine-grained histopathological patterns, resulting in suboptimal boundary delineation and model generalizability. To address these limitations, we propose a transformer-attention hybrid U-Net (TAH U-Net), integrating hybrid CNN-transformer encoding, attention-guided skip connections, and a multi-stage guided loss mechanism for enhanced segmentation accuracy and model interpretability. The ResNet50-based convolutional layers efficiently capture local spatial features, while Vision Transformer (ViT) blocks model global contextual dependencies, improving segmentation consistency. Attention mechanisms are incorporated into skip connections and decoder pathways, refining feature propagation by suppressing irrelevant tissue noise while enhancing diagnostically significant regions. A novel hierarchical guided loss function optimizes segmentation masks at multiple decoder stages, improving boundary refinement and gradient stability. Additionally, Explainable AI (XAI) techniques such as LIME, Occlusion Sensitivity, and Partial Dependence Analysis (PDP), validate the model's decision-making transparency, ensuring clinical reliability. The experimental evaluation on the SICAPv2 dataset demonstrates state-of-the-art performance, surpassing traditional U-Net architectures with a 4.6% increase in Dice Score, 5.1% gain in IoU, along with notable improvements in Precision (+ 4.2%) and Recall (+ 3.8%). This research significantly advances AI-driven prostate cancer diagnostics by providing an interpretable and highly accurate segmentation framework, enhancing clinical trust in histopathology-based grading within medical imaging and computational pathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.